Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Applications of 18 beta-glycyrrhetinic acid in preparing drugs used for treating allergic rhinitis

A technology for allergic rhinitis and glycyrrhetinic acid, which is applied in the field of medical applications and can solve problems such as undiscovered

Inactive Publication Date: 2016-05-25
张小兵
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no literature report on the inhibition of 18β-GA and its derivatives on allergic rhinitis (AR).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of 18 beta-glycyrrhetinic acid in preparing drugs used for treating allergic rhinitis
  • Applications of 18 beta-glycyrrhetinic acid in preparing drugs used for treating allergic rhinitis
  • Applications of 18 beta-glycyrrhetinic acid in preparing drugs used for treating allergic rhinitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1、18

[0050] The preparation of embodiment 1,18β-sodium glycyrrhetinate nasal drops

[0051] Weigh 8mg of 18β-sodium glycyrrhetinate, dissolve it in 0.267mL of normal saline, and magnetically stir to help dissolve; then use 0.033mL of water for injection to adjust the osmotic pressure to 280~310mmol / L, and adjust the pH to about 7.5 with an appropriate amount of hydrochloric acid, so that the 18β-licorice The final mass concentration of sodium hypochlorite was 2.67%. Inject 10ml of nasal drops into a special plastic bottle, seal and pack, and obtain 2.67% 18β-sodium glycyrrhetinate nasal drops for allergic rhinitis with a specification of 10ml / piece.

[0052] Method of use: nasal drops, 3 times / day, a course of treatment every 2 weeks, generally 1~2 courses of treatment.

Embodiment 2

[0053] Embodiment 2, the preparation of allergic rhinitis drops

[0054] Weigh 4mg of 18β-sodium glycyrrhetinate, dissolve it in 0.267mL of normal saline, and magnetically stir to aid dissolution; use 0.033ml of water for injection to adjust the osmotic pressure to 280~310mmol / L, and adjust the pH to about pH7.5 with an appropriate amount of hydrochloric acid, so that 18β- The final mass concentration of sodium glycyrrhetinate is about 1.34%. Inject 10ml of nasal drops into a special plastic bottle, seal and pack, and obtain 1.24% 18β-sodium glycyrrhetinate nasal drops for allergic rhinitis with a specification of 10ml / piece.

[0055] Method of use: nasal drops, 3 times / day, a course of treatment every 2 weeks, generally 1~2 courses of treatment.

Embodiment 3

[0056] Embodiment 3, the preparation of allergic rhinitis spray

[0057] Weigh 8mg of 18β-sodium glycyrrhetinate, dissolve it in 0.267mL of normal saline, and magnetically stir to help dissolve; then use 0.033mL of water for injection to adjust the osmotic pressure to 280~310mmol / L, and adjust the pH to about 7.5 with an appropriate amount of hydrochloric acid, so that the 18β-licorice The final mass concentration of sodium hypochlorite was 2.67%. Inject 10ml of micro-scaled special plastic bottle nasal spray, seal and pack, and get 2.67% 18β-sodium glycyrrhetinate allergic rhinitis treatment nasal spray with a specification of 10ml / piece.

[0058] Nasal spray nasal spray, 3 times / day, a course of treatment every 2 weeks, generally 1~2 courses of treatment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses novel pharmaceutical applications of 18 beta-glycyrrhetinic acid in preparing drugs used for treating allergic rhinitis, and belongs to the field of medical application. Sensitized Wistar rats are used for establishing AR animal models, behavioral scores of rat groups are compared in 2 weeks and 4 weeks after drug administration, and nasal septum mucous membranes are observed under electron microscopes. It is shown by obtained results that all the rat groups possess typical AR symptoms, behavioral superposed score is larger than 5, AR symptoms are relieved by 18 beta-glycyrrhetinic acid drug intervention, and the behavioral superposed score is reduced obviously comparing with that of model groups (P<0.01). It can be observed under electron microscopes that: thick mucus on the top of nasal cilliated epithelium of rat groups treated with 18 beta-glycyrrhetinic acid for 2 to 4 weeks is reduced gradually comparing with that of the model groups, and cilia adhesion, lodging, and falling are avoided gradually, so that it can be considered that 18 beta-glycyrrhetinic acid is capable of inhibiting pathologic changes of AR model rat nasal mucosa cilia obviously, and 18 beta-glycyrrhetinic acid can be used for preparing drugs used for treating allergic rhinitis.

Description

technical field [0001] The invention relates to a new medical application of 18β-glycyrrhetinic acid (18β-GA) in the preparation of medicines for treating allergic rhinitis, which belongs to the field of medical application. Background technique [0002] Allergic rhinitis (Allergicrhinitis, AR) is allergic rhinitis, which refers to the release of mediators (mainly histamine) mediated by IgE after atopic individuals are exposed to allergens, and there are a variety of immune active cells and cells Non-infectious inflammatory diseases of the nasal mucosa in which factors and other factors are involved. The typical symptoms of allergic rhinitis are mainly paroxysmal sneezing, clear watery nasal discharge, nasal congestion and nasal itching. Some are accompanied by hyposmia. Allergic rhinitis is the most common allergic disease of the respiratory tract. The incidence rate of AR in the global population is 10%-20%, and the incidence rate of preschool children in Beijing is as ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/56A61P11/02A61P29/00
Inventor 张小兵杨静席克虎侯赟
Owner 张小兵
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com